Bend Research, Inc.

Zalicus Pharmaceuticals, Ltd.

Pfizer Products Inc.

Miller, Warren Kenyon

Smithey, Daniel Tod

Frankamp, Benjamin Lee

Daniel Tod Smithey

Dwayne Thomas Friesen

Walter Christian Babcock

Warren Kenyon Miller

Ravi Mysore Shanker

William John Curatolo

Marshall David Crew

David Keith Lyon

Michael Mark Morgen

Corey Bloom

Ralph Tadday

Daniel Elmont Dobry

William Brett Caldwell

David Thomas Vodak

Abizer I Harianawala

Mahesh V Padval

Jeff T Gautschi

Roderick Jack Ray

Douglas Alan Lorenz

Leah Elizabeth Appel

Michael Jon Gumkowski

Michael E Perlman

Mark D Rabenstein

Brenda M Simpson

David Kenneth Lyon

Benjamin Lee Frankamp

Sheri L Shamblin

Corey Jay Bloom

Michael Ellis Pfizer Global Research & Development Perlman

Marc David Rabenstein

Michael Ellis Perlman

Mark David Rabenstein

Roger Benjamin Ruggeri

James Alan Schriver Nightingale

Ravi Mysore c/o Pfizer Global R&D Shanker

A pharmaceutical composition comprises a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer and a lipophilic microphase-forming material. Alternatively, a solid amorphous dispersion comprising a low-solubility drug and a concentration-enhancing polymer is co-administered with a lipophilic microphase-forming material to an in vivo use environment.

Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials

A pharmaceutical composition comprises a solid adsorbate comprising a drug adsorbed onto a substrate and a lipophilic microphase-forming material. The solid adsorbate may also be co-administered with a lipophilic microphase-forming material to an in vivo use environment. The compositions of the present invention enhance the concentration of drug in a use environment.

Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials

Pharmaceutical compositions are provided comprising an active agent and a dextran polymer derivative. The compositions include from 0.01 to 99 wt % of an active agent and from 1 to 99.99 wt % of a dextran polymer derivative. The dextran polymer derivative is selected from dextran acetate, dextran propionate, dextran succinate, dextran acetate propionate, dextran acetate succinate, dextran propionate succinate, dextran acetate propionate succinate, and mixtures thereof.

Pharmaceutical compositions of dextran polymer derivatives

A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug and a poorly aqueous soluble polymer, and a resuspending material selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethylcellulose, and pharmaceutically acceptable salt forms thereof.

Pharmaceutical compositions comprising nanoparticles and a resuspending material

A dosage form comprises a low-solubility drug, and a precipitation-inhibiting polymer. The drug is in a solubility-improved form and in the form of particles at least partially coated with the precipitation-inhibiting polymer.

Pharmaceutical dosage forms comprising a low-solubility drug and a polymer

Pharmaceutical compositions of a low-solubility drug and lower alkanoate-, phthalate- and trimellitate esters of hydroxypropyl methyl cellulose and lower alkanoate- and succinate esters of cellulose and methyl cellulose are disclosed that provide enhanced concentrations of the drug in a use environment.

Pharmaceutical compositions with enhanced performance

A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug, a poorly aqueous soluble non-ionizable cellulosic polymer, and a poorly aqueous soluble polymeric amphiphilic non-ionizable block copolymer.

Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer

Solid compositions of low-solubility drugs and poloxamers that provide concentration enhancement when administered to an aqueous environment of use are disclosed.

Solid compositions of low-solubility drugs and poloxamers

Disclosed are polymers of hydroxypropyl methyl cellulose acetate succinate (HPMCAS) and hydroxypropyl methyl cellulose acetate (HPMCA) with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compositions comprising a low-solubility drug and such polymers, the polymers provide enhanced aqueous concentrations and/or improved physical stability.

A pharmaceutical composition comprises nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a poorly aqueous soluble non-ionizable polymer.

Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer

Pharmaceutical compositions comprise a low-solubility drug adsorbed onto a high surface area substrate to form an adsorbate. The compositions in some embodiments include a concentration-enhancing polymer.

Pharmaceutical compositions of adsorbates of amorphous drug

The present invention relates to formulations and methods for increasing the bioavailability of 1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one, 1-(3,3-diphenylpropanoyl)piperazine, or a salt thereof. In particular, the formulation can include one or more pharmaceutically acceptable matrix polymers to form a solid dispersion, e.g., a spray dried dispersion or a hot melt extrusion.

Solid dispersion formulations and methods of use thereof

Growing community of inventors

Bend, OR, United States of America

Daniel Tod Smithey